Advertisement

Langenbeck's Archives of Surgery

, Volume 395, Issue 6, pp 697–706 | Cite as

Comparison of the long-term outcomes of uncinate process cancer and non-uncinate process pancreas head cancer: poor prognosis accompanied by early locoregional recurrence

  • Mee Joo Kang
  • Jin-Young JangEmail author
  • Seung Eun Lee
  • Chang-Sup Lim
  • Kuhn Uk Lee
  • Sun-Whe Kim
Original Article

Abstract

Purpose

The embryologic and anatomic peculiarity of the uncinate process may result in distinct clinical features, but few studies have addressed the uncinate process cancer. The purpose of this study was to compare the clinicopathologic characteristics and identify the prognostic factors that affect the survival and recurrence of pancreatic head cancer by tumor location.

Methods

Between January 2002 and December 2008, 453 patients (161 with uncinate and 292 with non-uncinate process cancer) were treated for pancreatic head cancer. Clinicopathologic variables were analyzed by tumor location.

Results

Invasion into the superior mesenteric artery (SMA) occurred more frequently (p < 0.001), and overall resectability (p = 0.003), curative resection (p < 0.001), and R0 resection rates (22.3% vs 35.6%; p = 0.003) were lower for uncinate process cancer. Furthermore, overall survival after R0 resection was lower for uncinate process cancer (median 21 vs 26 months; p = 0.018), and this was accompanied by more frequent (p = 0.038) and earlier (median 13 vs 52 months; p < 0.001) locoregional recurrence. Concurrent chemoradiation increased overall (median, 26 vs 13 months; p < 0.001) and disease-free survival (median, 15 vs 6 months; p < 0.001) of uncinate and non-uncinate process cancer, respectively, after curative-intended resection.

Conclusion

In uncinate process cancer, frequent invasion into the SMA led to lower resectability. Furthermore, lower survival after R0 resection was accompanied with frequent and early locoregional recurrence. Strategies to improve surgical and perioperative locoregional control are required for uncinate process cancer.

Keywords

Pancreatic cancer Recurrence Survival analysis 

Notes

Acknowledgments

This study was supported by a grant from the National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (no. 0820030).

Competing interest

None

References

  1. 1.
    Yamaguchi K (1992) Carcinoma of the uncinate process of the pancreas with a peculiar clinical manifestation. Am J Gastroenterol 87:1046–1050PubMedGoogle Scholar
  2. 2.
    Ye C, Xi PC, Hu XG (2003) Clinical analysis of uncinate process carcinoma of the pancreas. Hepatobiliary Pancreat Dis Int 2:605–608PubMedGoogle Scholar
  3. 3.
    Suzuki T, Kuratsuka H, Uchida K, Matsumoto Y, Honjo I (1972) Carcinoma of the pancreas arising in the region of the uncinate process. Cancer 30:796–800CrossRefPubMedGoogle Scholar
  4. 4.
    Li S, Pei YQ, Du FT, Ahuang GY, Li CY, Song QH et al (2002) Surgical treatment for uncinate process carcinoma of the pancreas. Hepatobiliary Pancreat Dis Int 1:592–594PubMedGoogle Scholar
  5. 5.
    Birk D, Schoenberg MH, Gansauge F, Formentini A, Fortnagel G, Beger HG (1998) Carcinoma of the head of the pancreas arising from the uncinate process. Br J Surg 85:498–501CrossRefPubMedGoogle Scholar
  6. 6.
    O'Rahilly R, Muller F (1978) A model of the pancreas to illustrate its development. Acta Anat (Basel) 100:380–385CrossRefGoogle Scholar
  7. 7.
    Kitagawa H, Ohta T, Makino I, Tani T, Tajima H, Nakagawara H et al (2008) Carcinomas of the ventral and dorsal pancreas exhibit different patterns of lymphatic spread. Front Biosci 13:2728–2735CrossRefPubMedGoogle Scholar
  8. 8.
    Makino I, Kitagawa H, Ohta T, Nakagawara H, Tajima H, Ohnishi I et al (2008) Nerve plexus invasion in pancreatic cancer: spread patterns on histopathologic and embryological analyses. Pancreas 37:358–365CrossRefPubMedGoogle Scholar
  9. 9.
    Atri M, Nazarnia S, Mehio A, Reinhold C, Bret PM (1994) Hypoechogenic embryologic ventral aspect of the head and uncinate process of the pancreas: in vitro correlation of US with histopathologic findings. Radiology 190:441–444PubMedGoogle Scholar
  10. 10.
    Inoue Y, Nakamura H (1997) Aplasia or hypoplasia of the pancreatic uncinate process: comparison in patients with and patients without intestinal nonrotation. Radiology 205:531–533PubMedGoogle Scholar
  11. 11.
    Seo HB, Lee JM, Kim IH, Kim SH (2009) Evaluation of the gross type and longitudinal extent of extrahepatic cholangiocarcinomas on contrast-enhanced multidetector row computed tomography. J Comput Assist Tomogr 33:376–382CrossRefPubMedGoogle Scholar
  12. 12.
    Han SS, Kim SW, Choi JI, Choi MG, Park YC, Jang JY, Park YH (2005) Determination of resectability for pancreatic cancer: based on the suspected vascular invasion in abdominal computed tomography. Korean J HBP Surg 9:55–61Google Scholar
  13. 13.
    Han SS, Jang JY, Kim SW, Kim WH, Lee KU, Park YH (2006) Analysis of long-term survivors after surgical resection for pancreatic cancer. Pancreas 32:271–275CrossRefPubMedGoogle Scholar
  14. 14.
    Griffin JF, Smalley SR, Jewell W, Paradelo JC, Reymond RD, Hassanein RE (1990) Patterns of failure after curative resection of pancreatic carcinoma. Cancer 66:56–61CrossRefPubMedGoogle Scholar
  15. 15.
    Barugola G, Falconi M, Bettini R, Boninsegna L, Casarotto A (2007) The determinant factors of recurrence following resection for ductal pancreatic cancer. JOP 9:132–140Google Scholar
  16. 16.
    Verbeke CS, Leitch D, Menon KV, McMahon MJ, Guillou PJ, Anthoney A (2006) Redefining the R1 resection in pancreatic cancer. Br J Surg 93:1232–1237CrossRefPubMedGoogle Scholar
  17. 17.
    Westgaard A, Tafjord S, Farstad IN, Cvancarova M, Eide TJ, Mathisen O et al (2008) Resectable adenocarcinomas in the pancreatic head: the retroperitoneal resection margin is an independent prognostic factor. BMC Cancer 8:5CrossRefPubMedGoogle Scholar
  18. 18.
    Esposito I, Kleeff J, Berqmann F, Reiser C, Herpel E, Friess H et al (2008) Most pancreatic cancer resections are R1 resections. Ann Surg Oncol 15:1651–1660CrossRefPubMedGoogle Scholar
  19. 19.
    American Joint Committee on Cancer (2002) Exocrine pancreas. In: AJCC cancer staging manual. Springer, New York, 157–164Google Scholar
  20. 20.
    Raut CP, Tseng JF, Sun CC, Wang H, Wolff RA, Crane CH et al (2007) Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg 246:52–60CrossRefPubMedGoogle Scholar
  21. 21.
    Haslam JB, Cavanaugh PJ, Stroup SL (1973) Radiation therapy in the treatment of irresectable adenocarcinoma of the pancreas. Cancer 32:1341–1345CrossRefPubMedGoogle Scholar
  22. 22.
    Moertel CG, Childs DS Jr, Reitemeir RJ, Colby MY Jr, Holbrook MA (1967) Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 2:865–867Google Scholar
  23. 23.
    Moertel CG, Frytak S, Hahn RG, O'Connell MJ, Reitemeier RJ (1981) Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil. The Gastrointestinal Study Group. Cancer 48:1705–1710CrossRefPubMedGoogle Scholar
  24. 24.
    Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H et al (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350:1200–1210CrossRefPubMedGoogle Scholar
  25. 25.
    Klinkenbijil JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH et al (1999) Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region. Phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Surg 230:776–784CrossRefGoogle Scholar
  26. 26.
    Chu QD, Khushalani N, Javle MM, Douglas HO Jr, Gibbs JF (2003) Should adjuvant therapy remain the standard of care for patinets with resected adenocarcinoma of the pancreas? Ann Surg Oncol 10:539–545CrossRefPubMedGoogle Scholar
  27. 27.
    Kennedy EP, Yeo CJ (2007) The case for routine use of adjuvant therapy in pancreatic cancer. J Surg Oncol 95:597–603CrossRefPubMedGoogle Scholar
  28. 28.
    Stocken DD, Büchler MW, Dervenis C, Bassi C, Jeekel H, Klinkenbijl JHG et al (2005) Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer 92:1372–1381CrossRefPubMedGoogle Scholar
  29. 29.
    National Comprehensive Cancer Network. Practice guidelines in oncology. http://www.nccn.org
  30. 30.
    Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A et al (2008) Fluorouracil vs. gemcitabine chemotherapy before and after fluorouracil-based chemoradiation after resection of pancreatic adenocarcinoma. A randomized controlled trial. JAMA 299:1019–1026CrossRefPubMedGoogle Scholar
  31. 31.
    Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schonekas H, Rost A et al (2006) Randomized phase iii trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24:3946–3952CrossRefPubMedGoogle Scholar
  32. 32.
    Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960–1966CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Mee Joo Kang
    • 1
  • Jin-Young Jang
    • 1
    Email author
  • Seung Eun Lee
    • 1
  • Chang-Sup Lim
    • 1
  • Kuhn Uk Lee
    • 1
  • Sun-Whe Kim
    • 1
  1. 1.Department of SurgerySeoul National University College of MedicineSeoulSouth Korea

Personalised recommendations